Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Effect of intestinal resection on quality of life in Crohn's disease
Author: Wright, E.
Kamm, M.
De Cruz, P.
Hamilton, A.
Ritchie, K.
Krejany, E.
Gorelik, A.
Liew, D.
Prideaux, L.
Lawrance, I.
Andrews, J.
Bampton, P.
Sparrow, M.
Florin, T.
Gibson, P.
Debinski, H.
Gearry, R.
Macrae, F.
Leong, R.
Kronborg, I.
et al.
Citation: Journal of Crohn's and Colitis, 2015; 9(6):452-462
Publisher: Oxford University Press
Issue Date: 2015
ISSN: 1873-9946
Statement of
Emily K. Wright, Michael A. Kamm, Peter De Cruz, Amy L. Hamilton, Kathryn J. Ritchie, Efrosinia O. Krejany, Alexandra Gorelik, Danny Liew, Lani Prideaux, Ian C. Lawrance, Jane M. Andrews, Peter A. Bampton, Miles P. Sparrow, Timothy H. Florin, Peter R. Gibson, Henry Debinski, Richard B. Gearry, Finlay A. Macrae, Rupert W. Leong, Ian Kronborg, Graeme Radford-Smith, Warwick Selby, Michael J. Johnston, Rodney Woods, P. Ross Elliott, Sally J. Bell, Steven J. Brown, William R. Connell, Paul V. Desmond
Abstract: Introduction: Patients with Crohn’s disease have poorer health-related quality of life [HRQoL] than healthy individuals, even when in remission. Although HRQoL improves in patients who achieve drug-induced or surgically induced remission, the effects of surgery overall have not been well characterised. Methods: In a randomised trial, patients undergoing intestinal resection of all macroscopically diseased bowel were treated with postoperative drug therapy to prevent disease recurrence. All patients were followed prospectively for 18 months. C-reactive protein [CRP], Crohn’s Disease Activity Index [CDAI], and faecal calprotectin [FC] were measured preoperatively and at 6, 12, and 18 months. HRQoL was assessed with a general [SF36] and disease-specific [IBDQ] questionnaires at the same time points. Results: A total of 174 patients were included. HRQoL was poor preoperatively but improved significantly [p < 0.001] at 6 months postoperatively. This improvement was sustained at 18 months. Females and smokers had a poorer HRQoL when compared with males and non-smokers, respectively. Persistent endoscopic remission, intensification of drug treatment at 6 months, and anti-tumour necrosis factor therapy were not associated with HRQoL outcomes different from those when these factors were not present. There was a significant inverse correlation between CDAI, [but not endoscopic recurrence, CRP, or FC] on HRQoL. Conclusion: Intestinal resection of all macroscopic Crohn’s disease in patients treated with postoperative prophylactic drug therapy is associated with significant and sustained improvement in HRQoL irrespective of type of drug treatment or endoscopic recurrence. HRQoL is lower in female patients and smokers. A higher CDAI, but not direct measures of active disease or type of drug therapy, is associated with a lower HRQoL.
Keywords: Crohn’s disease; inflammatory bowel disease; postoperative; health-related quality of life; biologicals; smoking
Rights: Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). All rights reserved.
DOI: 10.1093/ecco-jcc/jjv058
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.